Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2023-04-28 | Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University. We believe that Dr. Barker’s qualifications to serve on the Board of Directors include his extensive experience in senior leadership positions in the global pharmaceutical industry. |
| Filing Date | Source Excerpt |
|---|---|
| 2008-03-14 | Samuel L. Barker, Ph.D. has been a director since March 2000 and became chairman of our board of directors in March 2005. ... The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Kathleen M. Wiltsey. ... The following table presents summary information for the year ended December 31, 2007 regarding the compensation of the non-employee members of our board of directors. ... Samuel L. Barker, Ph.D. $49,279 Fees Earned or Paid in Cash, $63,176 Option Awards, Total $112,455. |
| 2009-03-13 | The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Kathleen M. Wiltsey. The board of directors, in its business judgment, has determined that Dr. Barker, Mr. Palantoni and Ms. Wiltsey are “independent” in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. |
| 2010-03-19 | The following table presents summary information for the year ended December 31, 2009 regarding the compensation of the non-employee members of our board of directors. Samuel L. Barker, Ph.D. $48,500 $14,946 — $63,446 Philippe J. Amouyal $30,500 $7,473 — $37,973 Raymond Debbane $32,000 $7,473 — $39,473 Robert J. Lefkowitz, M.D. $28,500 $7,473 $50,000 (4) $85,973 Alan S. Nies, M.D. $30,000 $7,473 $75,000 (5) $112,473 Frank P. Palantoni $37,000 $7,473 — $44,473 Christopher J. Sobecki $27,000 $7,473 — $34,473 Judith L. Swain, M.D. $29,500 $7,473 — $36,973 Kathleen M. Wiltsey $28,000 $7,473 — $35,473 |
| 2011-03-18 | The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Dr. Barker, Mr. Palantoni and Dr. Swain are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. The board of directors, in its business judgment, has also determined that Samuel L. Barker, Ph.D. is an “audit committee financial expert" as defined in Item 407(d)(5) of Regulation S-K. Each non-employee member of our board of directors currently receives the following cash compensation: an annual retainer of $15,000 for service on the board of directors ($30,000 for service as non-executive chairman of the board of directors), prorated for any partial year of service; an annual retainer of $2,500 for service on each committee of the board of directors of which he or she is a member ($5,000 for service as chairman of any such committee), prorated for any partial year of service; a fee of $2,500 for each meeting of the board of directors that he or she attends in person ($500 for each telephonic meeting of the board of directors in which he or she participates); and a fee of $1,000 for each committee meeting that he or she attends in person other than in connection with a meeting of the full board of directors ($500 for each telephonic committee meeting in which he or she participates). The following table presents summary information for the year ended December 31, 2010 regarding the compensation of the non-employee members of our board of directors. Samuel L. Barker, Ph.D. Fees Earned or Paid in Cash: $47,500, Option Awards: $23,958, Total: $71,458. |
| 2012-03-16 | Samuel L. Barker, Ph.D. has been a director since March 2000 and served as chairman of our board of directors from March 2005 to February 2012. Dr. Barker provides us with the benefit of his extensive experience in a wide variety of disciplines within the pharmaceutical industry. |
| 2013-03-25 | Samuel L. Barker, Ph.D. has been a director since March 2000 and served as chairman of our board of directors from March 2005 to February 2012. ... The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. ... The following table presents summary information for the year ended December 31, 2012 regarding the compensation of the non-employee members of our board of directors. ... Samuel L. Barker, Ph.D. $36,614 Fees Earned or Paid in Cash, $25,922 Option Awards, $19,999 Restricted Stock Awards, Total $82,535. |
| 2014-03-14 | The following table presents summary information for the year ended December 31, 2013 regarding the compensation of the non-employee members of our board of directors. Name: Samuel L. Barker, Ph.D. Fees Earned or Paid in Cash: $35,500 Option Awards: $30,074 Restricted Stock Awards: $30,074 All Other Compensation: $20,000 Total: $85,574 |
| 2015-03-13 | Samuel L. Barker, Ph.D. has been a director since March 2000. Audit Committee chair. Compensation Committee member. Director compensation table shows $80,965 total compensation in 2014. |
| 2016-03-18 | Samuel L. Barker, Ph.D. has been a director since March 2000 ... The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), ... The current members of our compensation committee are ... Samuel L. Barker, Ph.D. ... Director Compensation in 2015 ... Samuel L. Barker, Ph.D. $69,863 |
| 2017-03-17 | The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Dr. Barker, Mr. Palantoni and Dr. Swain are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. The board of directors, in its business judgment, has also determined that Samuel L. Barker, Ph.D. is an “audit committee financial expert" as defined in Item 407(d)(5) of Regulation S-K. ... Compensation Committee. Our compensation committee has been established to oversee the compensation of our employees, including our chief executive officer and other officers. ... The current members of our compensation committee are Mr. Palantoni (chair), Philippe J. Amouyal and Samuel L. Barker, Ph.D. The board of directors, in its business judgment, has determined that Mr. Palantoni, Mr. Amouyal and Dr. Barker are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. ... Director Compensation in 2016 ... Samuel L. Barker, Ph.D. ... $85,707 ... |
| 2018-03-16 | Samuel L. Barker, Ph.D. has been a director since March 2000. Dr. Barker provides us with the benefit of his extensive experience in a wide variety of disciplines within the pharmaceutical industry. The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. The current members of our compensation committee are Mr. Palantoni (chair), Philippe J. Amouyal and Samuel L. Barker, Ph.D. The board of directors, in its business judgment, has determined that Dr. Barker is “independent” in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. The following table presents summary information for the year ended December 31, 2017 regarding the compensation of the non-employee members of our board of directors. Samuel L. Barker, Ph.D. received total compensation of $83,424 in 2017. |
| 2019-03-15 | Samuel L. Barker, Ph.D. has been a director since March 2000. ... The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. ... The current members of our compensation committee are Mr. Palantoni (chair), Philippe J. Amouyal and Samuel L. Barker, Ph.D. ... The following table presents summary information for the year ended December 31, 2018 regarding the compensation of the non-employee members of our board of directors. ... Samuel L. Barker, Ph.D. $34,500 Fees Earned or Paid in Cash, $14,888 Option Awards, $19,999 Restricted Stock Awards, Total $69,387. |
| 2020-03-13 | The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. ... The current members of our compensation committee are Mr. Palantoni (chair), Philippe J. Amouyal and Samuel L. Barker, Ph.D. ... The following table presents summary information for the year ended December 31, 2019 regarding the compensation of the non-employee members of our board of directors. ... Samuel L. Barker, Ph.D. $63,067 Fees Earned or Paid in Cash, $24,460 Option Awards, $19,652 Restricted Stock Unit Awards, Total $107,179. |
| 2021-03-19 | Samuel L. Barker, Ph.D. has been a director since March 2000. The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. The current members of our compensation committee are Mr. Palantoni (chair), Philippe J. Amouyal and Samuel L. Barker, Ph.D. |
| 2022-04-08 | Samuel L. Barker, Ph.D. has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University. Dr. Barker provides us with the benefit of his extensive experience in a wide variety of disciplines within the pharmaceutical industry, including the development and commercialization of pharmaceutical products, the identification, evaluation and negotiation of collaborative agreements, and the management of pharmaceutical marketing and sales efforts, as well as his organizational and management skills developed while serving in his various leadership positions at Bristol-Myers Squibb and Clearview Projects. Director Compensation in 2021: $118,121. |
| 2023-03-17 | The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Frank P. Palantoni and Judith L. Swain, M.D. The board of directors, in its business judgment, has determined that Dr. Barker, Mr. Palantoni and Dr. Swain are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. The board of directors, in its business judgment, has also determined that Samuel L. Barker, Ph.D. is an “audit committee financial expert" as defined in Item 407(d)(5) of Regulation S-K. ... The current members of our compensation committee are Mr. Palantoni (chair), Philippe J. Amouyal and Samuel L. Barker, Ph.D. The board of directors, in its business judgment, has determined that Mr. Palantoni, Mr. Amouyal and Dr. Barker are “independent" in accordance with the applicable listing standards of The Nasdaq Stock Market, Inc. ... The following table presents summary information for the year ended December 31, 2022 regarding the compensation of the non-employee members of our board of directors. ... Samuel L. Barker, Ph.D. $72,500 Fees Earned or Paid in Cash, $20,387 Option Awards, $16,465 Restricted Stock Unit Awards, Total $109,352. |
| 2024-03-26 | Samuel L. Barker, Ph.D. has been a director since March 2000. Dr. Barker provides us with the benefit of his extensive experience in the pharmaceutical industry. The current members of our audit committee are Samuel L. Barker, Ph.D. (chair), Diane E. Sullivan and Judith L. Swain, M.D. The current members of our compensation committee are Philippe J. Amouyal (chair), Samuel L. Barker, Ph.D. and Judith L. Swain, M.D. The following table presents summary information for the year ended December 31, 2023 regarding the compensation of the non-employee members of our board of directors. Samuel L. Barker, Ph.D. received $74,633 in fees and $42,824 in stock awards in 2023, totaling $117,457. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22